Evidence map›Paper›PMID 26065687›Full record

ArticlePLoS neglected tropical diseases2015

Oral Wild-Type Salmonella Typhi Challenge Induces Activation of Circulating Monocytes and Dendritic Cells in Individuals Who Develop Typhoid Disease.

Franklin R Toapanta, Paula J Bernal, Stephanie Fresnay, Thomas C Darton, Claire Jones, Claire S Waddington, Christoph J Blohmke, Gordon Dougan, Brian Angus, Myron M Levine and 2 more

Open access · goldAbstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
4.1field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 28 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Further characterization ofFrontiers in immunology · 2023
    Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Transcriptomics in Human Challenge Models.Frontiers in immunology · 2017
    Review
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Franklin R ToapantaCenter for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland, United States of America; Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, United States of America.
Paula J BernalCenter for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland, United States of America; Department of Pediatrics, University of Maryland School of Medicine, Baltimore, Maryland, United States of America.
Stephanie FresnayCenter for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland, United States of America; Department of Pediatrics, University of Maryland School of Medicine, Baltimore, Maryland, United States of America.
Thomas C DartonOxford Vaccine Group, Department of Paediatrics, University of Oxford and the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre, Oxford, United Kingdom.
Claire JonesOxford Vaccine Group, Department of Paediatrics, University of Oxford and the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre, Oxford, United Kingdom.
Claire S WaddingtonOxford Vaccine Group, Department of Paediatrics, University of Oxford and the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre, Oxford, United Kingdom.
Christoph J BlohmkeOxford Vaccine Group, Department of Paediatrics, University of Oxford and the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre, Oxford, United Kingdom.
Gordon DouganMicrobial Pathogenesis Group, Wellcome Trust Sanger Institute, Hinxton, United Kingdom.
Brian AngusNuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
Myron M LevineCenter for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland, United States of America; Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, United States of America; Department of Pediatrics, University of Maryland School of Medicine, Baltimore, Maryland, United States of America.
Andrew J PollardOxford Vaccine Group, Department of Paediatrics, University of Oxford and the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre, Oxford, United Kingdom.
Marcelo B SzteinCenter for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland, United States of America; Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, United States of America; Department of Pediatrics, University of Maryland School of Medicine, Baltimore, Maryland, United States of America.
University of Maryland, Baltimore · USUniversity of Oxford · GBNational Institute for Health Research · GBWellcome Sanger Institute · GB

Funding

Wild-type S. typhi Infection in Humans: Integrated Immunoprotective MechanismsU19AI082655 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI GREENWALD, BRUCE D · 2009 to 2018
$27.8M
Shigella Live Vector-Based Multivalent VaccineU19AI109776 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI LEVINE, MYRON MAX · 2014 to 2018
$25.4M
IMMUNE MECHANISMS OF PROTECTION IN S TYPHI VACCINESR01AI036525 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI Marcelo B. Sztein · 1994 to 2026
$12.2M
FELLOWSHIP TRAINING PROGRAM IN VACCINOLOGYT32AI007524 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI Marcelo B. Sztein · 1997 to 2026
$6.4M
NIAID NIH HHS R01 AI036525NIAID NIH HHS R01-AI036525NIAID NIH HHS T32 AI007524NIAID NIH HHS T32-AI07524NIAID NIH HHS U19 AI082655NIAID NIH HHS U19 AI109776NIAID NIH HHS U19-AI109776Wellcome TrustWellcome Trust 092661
6 · The paper itself

Abstract

A new human oral challenge model with wild-type Salmonella Typhi (S. Typhi) was recently developed. In this model, ingestion of 104 CFU of Salmonella resulted in 65% of subjects developing typhoid fever (referred here as typhoid diagnosis -TD-) 5-10 days post-challenge. TD criteria included meeting clinical (oral temperature ≥38°C for ≥12 h) and/or microbiological (S. Typhi bacteremia) endpoints. One of the first lines of defense against pathogens are the cells of the innate immune system (e.g., monocytes, dendritic cells -DCs-). Various changes in circulating monocytes and DCs have been described in the murine S. Typhimurium model; however, whether similar changes are present in humans remains to be explored. To address these questions, a subset of volunteers (5 TD and 3 who did not develop typhoid despite oral challenge -NoTD-) were evaluated for changes in circulating monocytes and DCs. Expression of CD38 and CD40 were upregulated in monocytes and DCs in TD volunteers during the disease days (TD-0h to TD-96h). Moreover, integrin α4β7, a gut homing molecule, was upregulated on monocytes but not DCs. CD21 upregulation was only identified in DCs. These changes were not observed among NoTD volunteers despite the same oral challenge. Moreover, monocytes and DCs from NoTD volunteers showed increased binding to S. Typhi one day after challenge. These monocytes showed phosphorylation of p38MAPK, NFkB and Erk1/2 upon stimulation with S. Typhi-LPS-QDot micelles. In contrast, monocytes from TD volunteers showed only a moderate increase in S. Typhi binding 48 h and 96 h post-TD, and only Erk1/2 phosphorylation. This is the first study to describe different activation and migration profiles, as well as differential signaling patterns, in monocytes and DCs which relate directly to the clinical outcome following oral challenge with wild type S. Typhi.

Indexed as

Salmonella typhiAdolescentAdultBiomarkersDendritic CellsGene Expression RegulationHumansMiddle AgedMonocytesTyphoid FeverYoung AdultBiomarkers

Identifiers

PMID26065687
PMCPMC4465829
OpenAlexW2098909275

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.